A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-trans Retinoic Acid

Trial Profile

A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-trans Retinoic Acid

Recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs Arsenic trioxide (Primary) ; Tretinoin (Primary) ; Cytarabine; Dexamethasone; Dexamethasone; Idarubicin; Mitoxantrone
  • Indications Acute promyelocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 29 Jun 2015 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
    • 05 Jun 2015 Planned initiation date changed from 1 Apr 2015 to 1 Jun 2015, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top